FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 s

[News]

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.

More... (http://www.news-medical.net/news/20150601/FDA-clears-ADXS-HPV-plus-epacadostat-IND-for-HPV-associated-cervical-cancer-Phase-2-study.aspx)